These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 16510755)
1. Metabolic risk factors, drugs, and obesity. Padwal R; Majumdar S N Engl J Med; 2006 Mar; 354(9):974-5; author reply. PubMed ID: 16510755 [No Abstract] [Full Text] [Related]
2. Pharmacotherapy for obesity--promise and uncertainty. Yanovski SZ N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989 [No Abstract] [Full Text] [Related]
3. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. Després JP; Golay A; Sjöström L; N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982 [TBL] [Abstract][Full Text] [Related]
4. Novel therapies for cardiometabolic risk reduction and implications for clinical practice. Watson KE Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393 [TBL] [Abstract][Full Text] [Related]
5. Update on rimonabant--a selective cannabinoid CB1 antagonist. Boyd ST; Fremming BA Ann Pharmacother; 2006 May; 40(5):994. PubMed ID: 16638915 [No Abstract] [Full Text] [Related]
6. Less weight or more hype with rimonabant? Drug Ther Bull; 2007 Jun; 45(6):41-3. PubMed ID: 17583228 [TBL] [Abstract][Full Text] [Related]
7. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna. Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035 [No Abstract] [Full Text] [Related]
8. [Nutrition-obesity. Rimonabant and cardiovascular risk factors]. Vincent M; Golay A Rev Med Suisse; 2009 Jan; 5(185):49-52. PubMed ID: 19216325 [TBL] [Abstract][Full Text] [Related]
9. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. Kintscher U Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715 [No Abstract] [Full Text] [Related]
11. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? Di Marzo V Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695 [No Abstract] [Full Text] [Related]
12. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Gadde KM; Allison DB Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206 [No Abstract] [Full Text] [Related]
13. [The endocannabinoid system and treatment of obesity]. Aronsen L Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201 [TBL] [Abstract][Full Text] [Related]
15. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Scheen AJ; Van Gaal LF Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296 [TBL] [Abstract][Full Text] [Related]